Physician alerts to prevent symptomatic venous thromboembolism in hospitalized patients.
Gregory Piazza, Erin J Rosenbaum, William Pendergast...
https://pubmed.ncbi.nlm.nih.gov/19364975Actively Recruiting
Led by China-Japan Friendship Hospital · Updated on 2025-09-17
5800
Participants Needed
1
Research Sites
17 weeks
Total Duration
The trial investigates hospital-acquired venous thromboembolism (VTE) prevention among hospitalized patients in China, focusing on improving the use of preventive methods that are currently underutilized despite being safe and effective. This cluster-randomized clinical trial aims to evaluate whether a multifaceted quality improvement (QI) intervention is feasible and applicable in real-world hospital settings across China. The study is conducted within the China Pulmonary Thromboembolism Registry Study (CURES) group and seeks to increase the rate of at-risk patients receiving appropriate prophylaxis and reduce the incidence of hospital-associated VTE within 90 days after admission. Participating hospitals are randomized into two groups: an interventional group receiving multifaceted QI interventions and a control group following routine VTE prophylaxis based on current guidelines. The QI interventions include mandatory risk assessments, a computer alert system with clinical decision support and reminders, education initiatives, audit and feedback, distribution of clinical guidelines and pathways, and a mobile application to facilitate VTE risk assessment and communication between patients and physicians. The control group receives standard care or existing policies without these additional supports. During the study, eligible hospitalized patients will be monitored for appropriate prophylaxis use and the occurrence of VTE events, both symptomatic and asymptomatic, up to 90 days after hospital admission. Researchers will collect data on prophylaxis rates, VTE incidence, all-cause mortality, and complications related to the interventions. Weekly feedback reports will be provided to quality-control teams to ensure adherence to protocols. The total participation period includes hospitalization and a follow-up of 90 days post-admission, with various assessments and educational activities throughout the study.
CONDITIONS
CHIPs-VTE Study in Hospitalized Patients to Prevent Hospital-Acquired Venous Thromboembolism
You may qualify if you...
You will not qualify if you...
Complete this quick 3-step screening to check your eligibility
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Duration of hospital stay, at least 72 hours
Participants receive either the multifaceted quality improvement interventions including risk assessment, computer alerts, education, and audit, or routine venous thromboembolism (VTE) prophylaxis according to current clinical guidelines during their hospital stay.
Hospitalization period visits as part of routine care
Duration - Up to 90 days after hospital admission
Participants are monitored for up to 90 days after hospital admission to assess prophylaxis effectiveness and any complications.
Follow-up visits or contacts as per study protocol
Total: 1 location
1
China-Japan Friendship Hospital
Beijing, Beijing Municipality, China, 100029
Actively Recruiting
Z
Zhenguo Zhai, Doctor
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Gregory Piazza, Erin J Rosenbaum, William Pendergast...
https://pubmed.ncbi.nlm.nih.gov/19364975Menaka Pai, Nancy S Lloyd, Ji Cheng...
https://pubmed.ncbi.nlm.nih.gov/23279972Nils Kucher, Sophia Koo, Rene Quiroz...
https://pubmed.ncbi.nlm.nih.gov/15758007Writing Group for the CHECKLIST-ICU Investigators and the Brazilian Research in Intensive Care Network (BRICNet), Alexandre B Cavalcanti, Fernando Augusto Bozza...
https://pubmed.ncbi.nlm.nih.gov/27115264David A Garcia, Jessica Highfill, Katie Finnerty...
https://pubmed.ncbi.nlm.nih.gov/19584716A Fontaine, I Mahé, J F Bergmann...
https://pubmed.ncbi.nlm.nih.gov/16961674Fen Dong, Kaiyuan Zhen, Zhu Zhang...
https://pubmed.ncbi.nlm.nih.gov/32474204